Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 8 min ago
Peer-reviewedCC BY 4.0Molecular Therapy Oncology

ICAM-1 as a biomarker of efficacy for oncolytic coxsackievirus A21 in patient-derived Ewing sarcoma models

  1. 1Leeds Institute of Medical Research, University of Leeds, St James’s University Hospital, Wellcome Trust Brenner Building, Beckett Street, Leeds LS9 7TF, UK

Abstract

Ewing sarcoma (EWS) is a rare pediatric malignancy of the bone and soft tissue and requires better-tolerated and improved therapies. Oncolytic viruses (OVs) preferentially replicate in cancer cells, causing oncolysis, and activate both innate and adaptive anti-tumor immunity. Thus, OVs have the potential to generate long-lasting, systemic anti-cancer activity. Using a unique panel of patient-derived EWS cultures (PDES), recently derived from patient tumors at diagnosis and relapse, we have identified oncolytic coxsackievirus A21 (CVA21) as a candidate therapeutic OV in EWS, due to its high oncolytic activity and immune stimulation. PDES, unlike established EWS cell lines, expressed intercellular adhesion molecule-1 (ICAM-1), the CVA21 viral entry receptor, and were sensitive to CVA21-mediated oncolysis. Treatment with known ICAM-1 inducers, including tumor necrosis factor (TNF) and the clinically deliverable agent all-trans retinoic acid (ATRA), increased ICAM-1 expression and enhanced CVA21-induced oncolysis. Importantly, while CVA21 replication and oncolysis were inhibited by antiviral type I interferon, pre-treatment with ICAM-1 inducers (or CVA21-induced immune-mediated cytokines) overcame this inhibition. In addition to direct oncolysis, co-culture of CVA21-infected PDES with peripheral blood mononuclear cells (PBMCs) stimulated significant immune-mediated killing. This study presents pre-clinical evaluation of CVA21 using clinically relevant PDES samples and identifies CVA21 as a promising candidate for EWS immunotherapy.

Related

  1. Oncolytic viruses in combination cancer therapy: clinical lessons, biomarker-guided strategies, and future treatment directions
    Qingqing Wang, Qingqing Wang, Qingqing Wang +31
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyGeneral medicineDOAJFrontiersCrossref
  2. Antiviral humoral immunity as biomarker and effector in oncolytic adenovirus TILT-123 therapy
    Victor Arias, James H Clubb, Tatiana V Kudling +25
    Journal for Immunotherapy of CancerPeer-reviewedCC BY 4.0Full textGenetics & genomicsPMC
  3. Lung FDG-PET is an early pharmacodynamic biomarker of antiviral efficacy in preclinical influenza
    C. B. L. Victorio, A. Ganasarajah, S. Gupta +2
    bioRxivPreprintCC BY-NDFull textMicrobiologybioRxiv
  4. Circulating hepatocyte-derived extracellular particles as potential biomarker of steatohepatitis progression to fibrogenesis: Exploring the impact of smoking
    Oumnia Masrour, J Morvan, Alison Rapin +7
    Digestive and Liver DiseasePeer-reviewedCC BY-NC-ND 4.0Full text1 citedGeneral biologyEpidemiology & public healthHAL
  5. Exosomes as biomarker-diagnostics and therapeutics for multiple sclerosis: promise, pitfalls, and the rising role of milk-derived exosomes, towards next-generation precision medicine
    Charalampos Skarlis, Myrto Lantzi, Eleni Papakonstantinou +3
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0ImmunologyCrossref
BibTeX
@article{baugh2026icam1,
  title = {{ICAM-1 as a biomarker of efficacy for oncolytic coxsackievirus A21 in patient-derived Ewing sarcoma models}},
  author = {Richard T. Baugh and Tyler Barr and Elizabeth A. Roundhill and Fay Ismail and Milene Volpato and Graham P. Cook and Susan A. Burchill and Fiona Errington-Mais},
  journal = {Molecular Therapy Oncology},
  year = {2026},
  month = oct,
  doi = {10.1016/j.omton.2026.201367},
  url = {https://doi.org/10.1016/j.omton.2026.201367},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - ICAM-1 as a biomarker of efficacy for oncolytic coxsackievirus A21 in patient-derived Ewing sarcoma models
AU  - Richard T. Baugh
AU  - Tyler Barr
AU  - Elizabeth A. Roundhill
AU  - Fay Ismail
AU  - Milene Volpato
AU  - Graham P. Cook
AU  - Susan A. Burchill
AU  - Fiona Errington-Mais
PY  - 2026
DA  - 2026/10/14
JO  - Molecular Therapy Oncology
DO  - 10.1016/j.omton.2026.201367
UR  - https://doi.org/10.1016/j.omton.2026.201367
AB  - Ewing sarcoma (EWS) is a rare pediatric malignancy of the bone and soft tissue and requires better-tolerated and improved therapies. Oncolytic viruses (OVs) preferentially replicate in cancer cells, causing oncolysis, and activate both innate and adaptive anti-tumor immunity. Thus, OVs have the potential to generate long-lasting, systemic anti-cancer activity. Using a unique panel of patient-derived EWS cultures (PDES), recently derived from patient tumors at diagnosis and relapse, we have identified oncolytic coxsackievirus A21 (CVA21) as a candidate therapeutic OV in EWS, due to its high oncolytic activity and immune stimulation. PDES, unlike established EWS cell lines, expressed intercellular adhesion molecule-1 (ICAM-1), the CVA21 viral entry receptor, and were sensitive to CVA21-mediated oncolysis. Treatment with known ICAM-1 inducers, including tumor necrosis factor (TNF) and the clinically deliverable agent all-trans retinoic acid (ATRA), increased ICAM-1 expression and enhanced CVA21-induced oncolysis. Importantly, while CVA21 replication and oncolysis were inhibited by antiviral type I interferon, pre-treatment with ICAM-1 inducers (or CVA21-induced immune-mediated cytokines) overcame this inhibition. In addition to direct oncolysis, co-culture of CVA21-infected PDES with peripheral blood mononuclear cells (PBMCs) stimulated significant immune-mediated killing. This study presents pre-clinical evaluation of CVA21 using clinically relevant PDES samples and identifies CVA21 as a promising candidate for EWS immunotherapy.
SN  - 2950-3299
ER  -